Acquisition Of Solestial Strengthens U.S.-Based Space Solar Manufacturing Capabilities


York Space Systems announced it has entered into a definitive agreement to acquire Solestial, a provider of next-generation space solar technology, in a move designed to strengthen York’s supply chain and secure critical U.S.-based solar manufacturing capabilities for space applications.

Based in Tempe, Arizona, Solestial develops ultrathin, radiation-hardened silicon solar cells and modules specifically engineered for the space environment. The company is known for its self-healing silicon technology, which has already been proven on orbit and is designed to enable scalable, high-volume manufacturing.

York said the acquisition will help reduce reliance on Chinese-controlled materials and manufacturing while strengthening domestic production capabilities for mission-critical space systems. Following the transaction’s close, Solestial will operate as a wholly owned subsidiary of York while continuing to support customers across the commercial, civil, and national security markets.

The acquisition comes as demand for space-based power systems continues to increase across satellite constellations, national defense missions, and future lunar and deep-space initiatives. York noted that traditional III-V solar solutions remain expensive and constrained by long lead times, while terrestrial silicon alternatives are not optimized for radiation-heavy space environments.

York executives said integrating Solestial’s technology into its platform strategy will improve manufacturing reliability, scalability, and cost efficiency while enhancing control over critical subsystems.

Solestial has already established a growing U.S. manufacturing footprint, with approximately 95% of its supply chain currently based in the United States and plans to transition to fully domestic production. The company recently expanded its manufacturing capacity through the acquisition of advanced high-volume solar manufacturing equipment capable of supporting wafer-to-module production within the U.S.

The transaction is expected to close during the second quarter, subject to customary regulatory approvals and closing conditions.

York Space Systems is a U.S.-based defense and commercial space prime contractor that provides hardware and software solutions across the space mission lifecycle for government, national security, and commercial customers.

Solestial focuses on delivering scalable and affordable space solar technology through flexible, low-mass solar power modules engineered for long-duration use in space environments.

KEY QUOTES:

“York has consistently invested in U.S.-based manufacturing as a core part of how we deliver for our customers. This acquisition builds on that approach, strengthening our supply chain by investing in a proven U.S. company, supporting the domestic industrial base, and reducing reliance on foreign sources for critical materials and manufacturing.”

Dirk Wallinger, CEO, York Space Systems

“Solestial has proven a scalable, space-optimized solar technology that is designed to perform in ways legacy and terrestrial solutions cannot. That will give us the ability to build more capable platforms with better performance, lower cost, and greater design flexibility.”

Mike Lajczok, CTO, York Space Systems

“Solestial was founded to solve the space power bottleneck. Our customers need a solution that can scale, perform in space, and be manufactured reliably. Partnering with York allows us to accelerate all three; expanding production, deepening technical integration, and delivering a resilient, American-made capability to a broader set of missions.”

Margo de Naray, CEO, Solestial

 

Free Training

Source link

Acquisition Of U.S. Pharmaceutical Manufacturer Noble Pharma Expands Manufacturing Capabilities


Parnell, a veterinary pharmaceutical company, announced that it has acquired Noble Pharma, a U.S.-based pharmaceutical manufacturer, under a Securities Purchase Agreement dated November 26, 2025.

The acquisition adds an FDA- and DEA-accredited manufacturing facility to Parnell’s operations, strengthening its presence in the United States and supporting its long-term strategy to deliver high-quality products and reliable supply to customers and distribution partners. Noble Pharma’s capabilities enhance Parnell’s manufacturing footprint, improve supply continuity, and enable growth across its expanding product portfolio.

Noble Pharma, located in Menomonie, Wisconsin, produces a wide range of pharmaceutical formats, including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.

Parnell said the transaction positions the company to scale production, accelerate innovation, and better serve its growing customer base across the U.S. market and internationally. The company currently develops, manufactures, and commercializes animal health solutions for companion and production animals in 10 countries.

KEY QUOTE:

“Completing this acquisition marks an important milestone for Parnell. Noble Pharma’s operational excellence and established U.S. manufacturing footprint perfectly complement our mission to provide consistent supply, superior quality, and exceptional service to our partners and customers.”

Brad McCarthy, Chief Executive Officer of Parnell

Free Training

Source link

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States


  • Milestone marks progress against AbbVie‘s previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity
  • Supports production of AbbVie‘s current and next-generation immunology and neuroscience medicines
  • Transaction anticipated to close in mid-2026

AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West. The acquisition of the manufacturing site will significantly expand AbbVie‘s drug delivery device manufacturing capabilities and capacity.

AbbVie plans to hire approximately 200 employees at the site and invest more than $175 million to acquire, as well as modernize and fully integrate it into its global manufacturing network. The combination of this acquisition and associated planned investments are part of AbbVie‘s commitment to expanding its pharmaceutical manufacturing in the United States (U.S.), supporting innovation and improving patient access and outcomes.

“Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S.,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients’ lives.”

The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines.

With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its 11 U.S. manufacturing sites. When completed, this acquisition will significantly expand AbbVie‘s presence and economic impact in Arizona.

The transaction is anticipated to close in mid-2026, subject to closing conditions.

About AbbVie 

AbbVie‘s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn, FacebookInstagramX (formerly Twitter) and YouTube. 

Forward-Looking Statements  

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie‘s operations is set forth in Item 1A, “Risk Factors,” of AbbVie‘s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

 

Cision View original content:https://www.prnewswire.com/news-releases/abbvie-to-acquire-arizona-manufacturing-facility-further-strengthening-manufacturing-capabilities-in-the-united-states-302658118.html

SOURCE AbbVie



Free Training

Source link